Estrella Immunopharma, Inc. (ESLA) has a negative trailing P/E of -5.3, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -18.96%.
Criteria proven by this page:
Overall SharesGrow Score: 39/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2021 | -467.8 | 0.00 | 0.00 | 0.00 | - |
| 2022 | -34.7 | -0.03 | -56.26 | 0.00 | - |
| 2022 | -59.5 | 1.44 | 8.39 | 0.00 | - |
| 2024 | -5.3 | -0.23 | 9.06 | 0.00 | - |
| 2024 | -5.0 | -0.26 | 306.25 | 0.00 | - |
| 2025 | -4.4 | -0.11 | -5.54 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2020 | $-0.02 | $0.00 | $-733.69K | - |
| 2021 | $-0.29 | $0.00 | $-1.69M | - |
| 2022 | $-0.17 | $0.00 | $-996.1K | - |
| 2023 | $-0.21 | $0.00 | $-7.31M | - |
| 2024 | $-0.25 | $0.00 | $-8.85M | - |
| 2025 | $-0.35 | $0.00 | $-13.06M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.39 | $-0.39 – $-0.39 | $0.00 | $0.00 – $0.00 | 1 |
| 2027 | $-0.32 | $-0.32 – $-0.32 | $0.00 | $0.00 – $0.00 | 1 |
| 2028 | $-0.23 | $-0.23 – $-0.23 | $98.87M | $98.87M – $98.87M | 1 |
